Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic treatments1Unregulated biocopies, legal and regulatory decisions, and misaligned incentives within healthcare…
Source: www.globenewswire.com – Read more
Board-Ready Security Metrics That Actually Matter
TL;DR Board-ready security metrics translate technical capabilities into financial risk and business outcomes. Boards need visibility across three dimensions: risk exposure, incident response capability, and
